Utilidad clínica de la hormona antimülleriana en la predicción de la edad ovárica en España / Clinical use of antimüllerian hormone to predict ovarian age in Spain

Objetivo: la hormona antimülleriana es un marcador clínico de la reserva ovárica pero no disponemos de sus valores de referencia en la población española. Se han determinado sus valores de normalidad en relación a la edad en una amplia muestra de población española. Sujetos y métodos: se estudiaron 10.443 mujeres (edad 20-45 años). Todas las determinaciones séricas de hormona antimülleriana se realizaron mediante un test de ELISA (hormona antimülleriana Gen II ELISA assay; Beckman Coulter, Brea, CA, USA). Resultados: la edad media fue 36,6 ± 4,3 años. Los niveles de la hormona antimülleriana se correlacionaron inversamente con la edad (r = −0,35; p < 0,001). La edad ovárica aumentaba 1 año por cada descenso medio de 0,2 ng/ml de hormona antimülleriana. Se obtuvieron diferencias significativas en los valores de hormona antimülleriana entre Cataluña, Baleares y Andalucía. Conclusiones: este estudio ofrece estimaciones de los valores de referencia de hormona antimülleriana en función de la edad y contribuye a determinar con mayor precisión la reserva ovárica de las mujeres españolas (AU)

Objetives: Antimüllerian hormone is considered clinically useful in the evaluation of ovarian reserve, and few data exists regarding its distribution in the Spanish population. We determine normality values of antimüllerian hormone related to age in a large Spanish community cohort. Subjects and methods: We study 10,443 women (aged 20-45). Antimüllerian hormone values were analysed using an ELISA assay (antimüllerian hormone Gen II ELISA assay; Beckman Coulter, Brea, CA, USA). Results: The mean age of women was 36.6 ± 4.3 years. Antimüllerian hormone values were inversely correlated with age (r = −0.35; p < 0.001). From the regression equation, the estimated yearly decrease in antimüllerian hormone was 0.2 ng/ml. Significant differences were obtained in mean values of antimüllerian hormone among Cataluña, Baleares, and Andalucía. Conclusions: This study reports the distribution of antimüllerian hormone values in different age groups in Spain, and contribute to determine the ovarian reserve in Spanish women (AU)

End user evaluation of DG-PT L Rec, a human recombinant thromboplastin in liquid formulation.

The objective is to evaluate Grifols' DG-PT L Rec liquid reagent for prothrombin time (PT) determination in comparison to the laboratory's reference reagent (Siemens' Thromborel S). For linearity, the average master curve for PT and five nominal prothrombin concentrations was obtained from five calibration curves. Within-assay precision (repeatability) was calculated after measuring 20 successive tests of normal and pathological controls. For correlation, 581 routine clinical citrated plasma samples were assessed with both reagents. The BCS XP hemostasis analyzer was used. Linearity of the DG-PT L Rec was good (P < 0.001). The coefficient of variation met the desirable imprecision of less than 2% (normal controls: 1.7%; pathological controls: 0.9%). Correlation between DG-PT L Rec and Thromborel S was high (r = 0.9795; PT in %). In subgroups of anticoagulated, low fibrinogen, lipemic, jaundice, and hemolyzed samples the correlation was more than 0.95. Performance of DG-PT L Rec was high and comparable to the reference reagent.